NCT04925167View on ClinicalTrials.gov

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Respiratory Failure
Interventions
DRUG

Argatroban

Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.

DRUG

unfractionated heparin

unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.

Trial Locations (1)

100020

Bing Sun, Beijing

All Listed Sponsors
lead

Beijing Chao Yang Hospital

OTHER